Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
OLIG2 CRISPR/Cas9 KO Plasmid (h2): sc-400670-KO-2
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- OLIG2 CRISPR/Cas9 Knockout (KO) Plasmid (h2) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the OLIG2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: OLIG2 Antibody (1G11): sc-293163
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
OLIG2 CRISPR/Cas9 KO Plasmid (h2) | sc-400670-KO-2 | 20 µg | $397.00 |
Overview
OLIG2 encodes a basic helix-loop-helix transcription factor that orchestrates neural development by regulating lineage specification and differentiation of oligodendrocyte progenitors and motor neuron precursors. In concert with developmental signaling inputs such as Sonic hedgehog and Notch, OLIG2 controls gene expression programs that influence cell-cycle progression, chromatin state, and glial fate commitment in the central nervous system. Dysregulated OLIG2 expression and altered downstream transcriptional networks are implicated in malignant glioma biology, including shifts in progenitor-like states and resistance-associated cellular programs. These features make OLIG2 a useful target for studying neurodevelopmental transcriptional circuitry and tumor-associated lineage plasticity.
OLIG2 CRISPR/Cas9 KO Plasmid (h2) is a pool of plasmids designed for targeted disruption of the OLIG2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the OLIG2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the OLIG2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish OLIG2 protein expression.
This CRISPR knockout system enables efficient generation of OLIG2-deficient cell models for investigation of OLIG2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting OLIG2 exon(s) critical for OLIG2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple OLIG2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by OLIG2 CRISPR/Cas9 KO Plasmid (h) and OLIG2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the OLIG2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by OLIG2 HDR Plasmid (h) and OLIG2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by OLIG2 homology arms to support homology-directed repair at defined OLIG2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.